ClinicalTrials.gg
RecruitingNCT07129941Updated Aug 19, 2025

Unified Protocol Group Treatment in a University Outpatient Clinic

An interventional study of Unified Protocol in Emotional Disorders, Anxiety and Depression - Major Depressive Disorder, sponsored by University of Bergen. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by University of Bergen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Anxiety Disorders with a site in Norway — 22 open to participants now, 32 under way, none of them phase 3. Anxiety Disorders · Norway.

Planned enrollment
38th of 72
140 · median 155
Started
2025
with 8 others
No phase
63 of 92
19 open now
Primary completion
2028-12
later than 27 of 31 live
Registered
81st of 92
by date
Lead sponsor
5 of 92
University of Bergen

Among the 92 studies in Anxiety Disorders with a site in Norway, this one is the 38th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2025, is one of 63 with no phase, reaches primary completion later than 27 of the 31 other live ones, and was the 81st registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

22 of the 92 studies in Anxiety Disorders with a site in Norway are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Anxiety Disorders with a site in Norway, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate the effectiveness and underlying processes of change of the Unified Protocol (UP) for treating emotional disorders in a university outpatient clinic. The study will involve 140 patients receiving UP treatment in a group format, delivered either by experienced or novice therapists, along with a non-clinical control group of 45 participants. Participants will self-refer on the basis of advertisement about the study through flyers, posters, project website, social media or local news media. Outcomes will be assessed through self-report measures of well-being, symptoms, emotion regulation, and the non-specific factors of treatment credibility and therapeutic alliance. Additionally, psychophysiological measures of heart rate variability and interoception will be used to explore processes influencing treatment response. Qualitative interviews will complement the quantitative data by capturing participants' perspectives on the treatment and experiences of what contributed to change.

Read the detailed description

Background Anxiety and depression are the most common mental disorders, incurring vast personal and societal costs. While effective evidence-based treatments exist, healthcare systems struggle to meet the growing demand for services. A key challenge in delivering care is that most treatments are diagnosis specific. This complicates training and implementation due to clinicians having to learn multiple treatment manuals. In addition, these single-disorder treatments may also often have poor applicability to the complex symptoms and patterns of comorbidity typically seen in real-world clinical settings. As a response to these challenges, several transdiagnostic treatment protocols have been developed to target psychological processes underlying different diagnoses. One such model is the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP) developed by David Barlow and colleagues. UP addresses the functional processes that maintain emotional disorders, such as negative reactions to emotions and avoidance behaviors.

The Unified Protocol (UP) has shown non-inferiority to diagnosis-specific CBT and superiority to treatment as usual in both individual and group formats. Meta-analyses confirm its effectiveness for comorbid emotional disorders and suggest potential for cost-effective, scalable implementation.

Knowledge gaps

  • Norwegian Setting: Only one small feasibility study of UP has been conducted in Norway. A larger naturalistic trial is needed to assess outcomes (quality of life, functioning, symptoms) and potential negative effects in a public health context.
  • Processes of Change: More research is needed to identify active treatment mechanisms (e.g., emotion regulation, mindfulness, cognitive flexibility) and their association with outcomes in group UP. Non-specific factors such as credibility and group alliance also require investigation.
  • Psychophysiological Measures: UP's impact on objective emotion regulation markers (e.g., heart rate variability, interoception) is unexplored. Inclusion of such measures can reduce bias and clarify underlying mechanisms.
  • Novice Therapists: The ability of graduate psychology students to deliver UP with high fidelity in group format remains unclear and merits further investigation.

Study objectives This study aims to explore outcomes, processes of change, and user experiences of UP group treatment for patients with emotional disorders in a naturalistic clinical sample in a Norwegian setting. Additionally, it will compare the clinical sample to a healthy control group to better understand how transdiagnostic characteristics serve as vulnerability or resilience factors in the development of emotional disorders. Lastly, the study examines whether novice therapists can be trained to deliver the treatment with high levels of fidelity based on ratings of adherence and competence.

Main aims and research questions i. Assessing treatment effectiveness: To determine whether UP group treatment leads to improvements in key clinical outcomes, identify factors that influence these outcomes, and assess any negative treatment effects.

Research questions:

  • Does UP group treatment lead to improvements in quality of life, everyday functioning, emotion regulation, and self-reported symptoms?
  • To what extent do clinical and demographic factors impact treatment adherence and outcome?
  • What type and frequency of negative treatment effects do participants report?

ii. Examining processes of change: To investigate the role of emotion regulation, interoception, and UP skill use as predictors and mediators of treatment outcomes, using both self-report and objective measures.

Research questions:

  • Specific factors: To what extent do changes in UP-relevant skills and processes (e.g., emotion regulation, acceptance, cognitive flexibility, and interoception) predict or mediate outcomes?
  • Non-specific factors: To what extent do treatment expectations and group alliance predict outcomes?

iii. Understanding patients' experience of UP: To explore patients' experience of UP treatment through in-depth qualitative interviews.

Research questions:

  • How do participants describe their experience of benefits and challenges with the UP program?
  • How do participants describe their experience of change during and after the treatment?

iv.) Understanding transdiagnostic factors in emotional vulnerability and resilience: To explore whether individuals with emotional disorders differ cross-sectionally from healthy controls.

Research question:

- Do patients with emotional disorders differ significantly from healthy controls on measures of emotion regulation, acceptance, cognitive flexibility, and psychophysiological markers (interoception, heart rate variability)?

v.) Examining UP group therapy delivered by novices: To assess whether novice therapists can be trained to deliver UP with high fidelity.

Research question:

- Can novice therapists (i.e., graduate students in clinical psychology under supervision) be trained to high levels of fidelity in delivering the UP group treatment?

03

Conditions studied

  • Emotional Disorders
  • Anxiety
  • Depression - Major Depressive Disorder

Keywords

  • Unified Protocol
  • Transdiagnostic treatment
  • Emotional disorders
  • Anxiety
  • Depression
  • Group therapy
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-40
  • Fulfilling diagnostic criteria for an anxiety disorder and/or unipolar depression (ICD F.3x - 4x)
  • Motivated for short-term treatment in group format

Exclusion criteria

Exclusion Criteria:

  • Suicidality
  • Self-harm
  • Severe psychiatric disorder (bipolar disorder, psychosis)
  • Substance use disorders
  • Use of anxiolytic medication (i.e., benzodiazepines)
  • Unstable antidepressant medication (i.e., stable dosage \<6 months)
  • Other ongoing psychological treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Unified Protocol group treatment

    The Unified Protocol (UP) is a time-limited modular treatment addressing core emotion regulation difficulties in patients with emotional disorders. There will be 8-10 patients and two or three therapists in the group. Treatment consists of one individual session of diagnostic assessment, and one or two individual preparation sessions (case formulation and goal setting), and 12 weekly 2 ½ hour group treatment sessions.

    Behavioral: Unified Protocol

Interventions

  • BehavioralUnified Protocol

    The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format

06

What researchers measure

Primary outcomes

  1. WHO-5: Wellbeing index

    The WHO-5 is a self-report measure of positive mental health. It consists of five items that are rated on a 6-point scale from 'All of the time' to 'At no time'. High scores indicate a more positive rating of wellbeing

    Time frame: From enrollment to follow-up at 6 months

Secondary outcomes

  1. Work and Social Adjustment Scale

    The WSAS is a five-item scale that addresses impairments in work/study, home, social life, private leisure activities, and interpersonal relations. Each item is self-rated on a nine-point Likert scale that ranges from "Not at all" (0) to "Severely impaired" (8).

    Time frame: From enrollment to follow-up at 6 months

  2. Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a nine-item scale measuring depression severity. Each item is self-rated on a four-point Likert scale that ranges from "Not at all" (0) to "Nearly every day" (3).

    Time frame: From enrollment to follow-up at 6 months

  3. Generalized Anxiety Disorder Scale (GAD-7)

    The GAD-7 is a seven-item scale measuring anxiety severity. Each items is self-rated on a four point Likert scale that ranges from "Not at all" (0) to "Nearly every day" (3).

    Time frame: From enrollment to follow-up at 6 months

  4. Multidimensional Emotional Disorders Inventory (MEDI)

    The MEDI is a 49-item scale measuring nine transdiagnostic factors involved in emotional disorders. Each item is self-rated on a nine point Likert scale that ranges from 0 (Not at all characteristic of me) to 8 (Totally characteristic of me). The dimensions measured are Neurotic temperament, positive temperament, depressive mood, autonomic arousal, somatic anxiety, intrusive thoughts, traumatic re-experiencing and avoidance.

    Time frame: From enrollment to follow-up at 6 months

  5. Level of Personality Functioning Scale Brief Form (LPFS-BF)

    The LPFS-BF is a 12-item scale measuring the level of personality functioning based on the Criterion "A" of the alternative model for personality disorders in the DSM-5; Identity, self-direction, empathy and intimacy. Each item is self-rated on a 4-point Likert scale that ranges from 0 (Little or no impairment) to 3 (Severe impairment).

    Time frame: From enrollment to follow-up at 6 months

  6. Difficulty in Emotion Regulation Scale (DERS-16)

    The DERS is a 16-item scale measuring individuals' typical levels of difficulties in emotion regulation. Each item is self-rated on a 5-point Likert scale that ranges from 1 (Almost never) to 5 (Almost always).

    Time frame: From enrollment to follow-up at 6 months

  7. Acceptance and Action Questionnaire- version 2 (AAQ-II)

    The AAQ-II is a 7-item scale measuring experiential avoidance and psychological inflexibility. Each item is self-rated on a 7-point Likert scale that ranges from 1 (Never right) to 5 (Always right). The total score ranges between 0-49. Higher scores indicate less psychological flexibility and more experiential avoidance.

    Time frame: From enrollment to follow-up at 6 months

  8. Five Facet Mindfulness Questionnaire (FFMQ)

    The FFMQ is a 15-item scale measuring mindfulness with regard to thoughts, experiences, and actions in daily life. Each item is self-rated on a 5-point Likert scale that ranges from 1 (Never or rarely true) to 5 (Very often or always true).

    Time frame: From enrollment to follow-up at 6 months

  9. Unified Protocol Cognitive Skills Questionnaire (UP-CSQ)

    The UP-CSQ is a 7-item scale measuring the cognitive skills taught in the UP. Each item is self-rated on a 5-point Likert scale that ranges from 1 (Never) to 5 (Always or when needed)

    Time frame: From enrollment to follow-up at 6 months

  10. Multidimensional Assessment of Interoceptive Awareness-2 (MAIA)

    The MAIA is a 37-item scale measuring interoceptive awareness. Each item is self-rated on a 6-point Likert scale that ranges from 0 (Never) to 5 (Always).

    Time frame: From enrollment to follow-up at 6 months

  11. Overall Anxiety Severity and Impairment Scale (OASIS)

    The OASIS is a 5-item scale measuring the frequency and severity of anxiety, avoidance, work/school/home interference, and social interference due to anxiety. Each item is self-rated on a 5-point Likert scale that ranges from 0 (None, never) to 4 (Extreme, constant). The OASIS is used as an in-session UP measures to examine processes of change

    Time frame: At each treatment session through the 12 weeks of treatment

  12. Overall Depression Severity and Impairment Scale (ODSIS)

    The ODSIS is a 5-item scale measuring the frequency and severity of depression symptoms, avoidance, work/school/home interference, and social interference due to depression. Each item is self-rated on a 5-point Likert scale that ranges from 0 (None/never) to 4 (Extreme/constant). The ODSIS is used as an in-session UP measures to examine processes of change

    Time frame: At each treatment session through the 12 weeks of treatment

  13. Unified Protocol Skill Use Scale (UPSUS)

    The UPSUS is a 7-item scale measuring the frequency with which individuals use UP-skills in distressing situations. Each item is self-rated on a 6-point Likert scale that ranges from 0 (Not at all) to 5 (Nearly all the time). Each item was written to describe core skills taught in each of the five core UP-modules. The UPSUS is used as an in-session UP measure to examine processes of change

    Time frame: At each treatment session through the 12 weeks of treatment

  14. Dimension of Skillfulness and Use Scale (DSUS)

    The DSUS is a 4-item scale measuring the understanding of UP skills learned in the prior session, frequency of skill use, quality of skill use, and effectiveness and skill use. Each item is self-rated on a 5-point Likert scale that ranges from 0 (Not at all) to 4 (Extremely well/every day). The DSUS is used as an in-session UP measures to examine processes of change

    Time frame: At each treatment session through the 12 weeks of treatment

  15. Client Satisfaction Questionnaire (CSQ-8)

    The CSQ-8 is an 8-item scale measuring clients' satisfaction with treatment. Each item is scored on a 4-point Likert scale that ranges from 0 to 3.

    Time frame: At final treatment session (week 12)

  16. The Negative Effects Questionnaire (NEQ)

    The NEQ is a 32-item scale measuring adverse or unwanted events during treatment. Each item is designed to assess adverse effects related to psychological treatments. Items are scored on a five-point Likert scale (0-4) and differentiates between treatment-related negative effects and those from external factors.

    Time frame: At final treatment session (week 12)

  17. The Heartbeat Counting Task (HBC)

    The HBC task evaluates three dimensions of interoception: 1) Interoceptive accuracy in the form of ratio of detected to actual heartbeats, 2) Interoceptive sensibility in the form of self-reported interoception through interviews and questionnaires, and 3) Interoceptive awareness in the form of metacognitive awareness of accuracy, measured by the correlation between confidence and actual performance using receiver operating characteristics (ROC) curve analysis.

    Time frame: From enrollment to follow-up at 6 months

  18. Heart Rate Variability (HRV) via a 24-hour ECG Monitoring.

    24-hour ECG data will be collected using BioPoint sensors from SiFi Labs, which are wearable, small and designed for continuous monitoring. The sensor is placed below the sternum. The data are not intended for clinical evaluation of heart function but suitable for investigating potential changes in HRV before and after psychotherapy in addition to possible differences in HRV in groups of patients with emotional disorders compared to healthy controls.

    Time frame: From enrollment to follow-up at 6 months

Other outcomes

  1. Credibility Rating Scale

    The version of the Credibility Rating Scale used in this study is a 5-item adapted version of the original Credibility Rating Scale developed by Devilly \& Borkovec.

    Time frame: This scale will be administered only at pre-treatment as a possible predictor of change.

  2. Group Session Rating Scale (GSRS)

    The GSRS is a 4-item scale measuring each participant's experience of alliance in the UP group therapy. Each item is scored on a visual analog scale, covering the patient's experience of the quality of the relations to both the therapist and the other patients in the group, the personal relevance of the goals and themes of the group session, the fit of the approach utilized in the treatment, and the general experience of being part of the group.

    Time frame: At each treatment session through the 12 weeks of treatment

07

Study locations

1 of 1 sites recruiting
  • Department of Clinical Psychology
    Bergen, Vestland 5009, Norway
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2028, 43 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 43 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Aug 19, 2025
StartActual
May 8, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2034
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07129941
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
May 8, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2034 (estimated)
Last update
Aug 19, 2025

Study contacts

Jon Vøllestad, Ph.D.
Contact
jon.vollestad@uib.no
0047 95 21 32 86
Elisabeth Schanche, Ph.D.
Contact
elisabeth.schanche@uib.no
0047 97 77 42 17
Jon Vøllestad, Ph.D.
principal investigator · University of Bergen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion